Zalevsky Jonathan's Form 4 filing
Nektar Therapeutics (NKTR) · filed Jun 17, 2026
- Accession no.
- 0001193125-26-274534
- Filed
- Jun 17, 2026
- Trade date
- Jun 15, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $336.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zalevsky JonathanCIK 0001789857 | Officer (Chief R&D Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Common Stock | SSaleDisposed | −5,538 | $60.71F2 | −$336,211.98 | 15,437 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $60.06 to $61.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Referenced by the price of 1 transaction in Table I.